Related Experiment Video
Updated: Aug 2, 2026
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Diversity of metabolic features and relevance to clinical subtypes of gliomas
Pushan Dasgupta1, Vinay K Puduvalli1
1Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Abstract:
Gliomas carry a dismal prognosis and have proven difficult to treat. Current treatments and efforts to target individual signaling pathways have failed. This is thought to be due to genetic and epigenetic heterogeneity and resistance. Therefore, interest has grown in developing a deeper understanding of the metabolic alterations that represent drivers and dependencies in gliomas. Therapies that target glioma-specific metabolic dependencies overcome the challenges of disease heterogeneity. Here, we present the diverse metabolic features of each current clinical subtype of glioma. We believe that this approach will enable the development of novel strategies to specifically target the various clinical and molecular subtypes of glioma using these metabolic features.
Insights
Gliomas are hard to treat due to genetic diversity. Targeting specific metabolic changes offers a new strategy for treating different glioma subtypes.
Area of Science:
- Oncology
- Metabolic pathways
- Cancer biology
Background:
- Gliomas have a poor prognosis and are resistant to current treatments.
- Targeting single signaling pathways has been ineffective due to tumor heterogeneity and resistance.
- Understanding metabolic alterations in gliomas is crucial for developing new therapies.
Purpose of the Study:
- To explore the diverse metabolic features across different clinical glioma subtypes.
- To identify glioma-specific metabolic dependencies that can be targeted therapeutically.
- To enable the development of novel, subtype-specific treatment strategies.
Main Methods:
- Analysis of metabolic profiles across various glioma subtypes.
- Identification of key metabolic pathways driving glioma growth and survival.
- Correlation of metabolic features with clinical and molecular characteristics.
Main Results:
- Detailed characterization of the distinct metabolic landscapes of glioma subtypes.
- Identification of specific metabolic dependencies unique to certain glioma types.
- Demonstration of metabolic heterogeneity as a key factor in treatment resistance.
Conclusions:
- Metabolic alterations are central to glioma pathogenesis and heterogeneity.
- Targeting glioma-specific metabolic dependencies presents a promising therapeutic avenue.
- Exploiting metabolic features can lead to more effective, subtype-specific treatments for gliomas.
